{"id":"https://genegraph.clinicalgenome.org/r/bb8d63ac-09eb-4662-8b5d-79d55a971f1fv1.0","type":"EvidenceStrengthAssertion","dc:description":"The relationship between *MSTO1* and primary mitochondrial disease was evaluated using the ClinGen Clinical Validity Framework as of May 18, 2023. *MSTO1* encodes Misato mitochondrial distribution and morphology regulator 1, an outer mitochondrial membrane protein that plays a role in mitochondrial fusion. \n\nThe *MSTO1* gene was first reported in relation to autosomal recessive primary mitochondrial disease in 2017 (PMID: 28544275), in two infants with cerebellar atrophy, developmental delay, myopathy, and elevated serum creatine kinase (CK) levels. Subsequent publications have shown a highly consistent phenotype of infantile onset (<2 years) cerebellar atrophy, myopathy, mild serum CK elevations, developmental delays, and ataxia with or without retinitis pigmentosa. Notably, at the same time of the initial report, a case with proposed dominant inheritance was reported (PMID:2855494), however, since no subsequent dominant cases have been reported (and 22 autosomal recessive cases with a clear and consistent phenotype have been reported), this GCEP elected to curate this gene-disease relationship as an autosomal recessive condition. The possibility of different mechanisms of action leading to both dominant and recessive inheritance cannot be excluded, but additional cases are needed to support autosomal dominant inheritance of *MSTO1*-related disease. Furthermore, while various names have been given to the constellation of features seen in those with *MSTO1*-related disease, pathogenic variants in this gene cause a primary mitochondrial disease. Therefore, the *MSTO1* phenotype has been lumped into one disease entity according to the ClinGen Lumping and Splitting Framework.\n\nEvidence supporting this gene-disease relationship includes case-level data and experimental data. This curation included 13 unique variants (including one nonsense, one frameshift, two splicing, and nine missense variants) in eight probands (although more than 20 probands have been reported in the medical literature) across at least five publications from 2017-2021 (PMIDs: 28544275, 29339779, 30684668, 31463572, 33612823). Loss-of-function is implicated as a mechanism of disease. This gene-disease association is also supported by numerous Drosophila melanogaster models (PMIDs: 29255146, 9144213), functional alteration in non-patient cells showing mitochondrial fragmentation (PMID: 17349998), absence of wild type MSTO1 expression in affected patients but not controls (PMID: 31463572), and rescue of mitochondrial morphology and fusion deficits in patientsâ€™ cells transduced with wild type MSTO1 (PMID: 31463572). \n\nIn summary, there is definitive evidence to support the relationship between *MSTO1* and primary mitochondrial disease. This has been repeatedly demonstrated and upheld over time, and no convincing evidence has emerged that contradicts this gene-disease relationship. This classification was approved by the NICHD/NINDS U24 ClinGen Mitochondrial Disease Gene Curation Expert Panel on on May 18, 2023. \n","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/bb8d63ac-09eb-4662-8b5d-79d55a971f1f","GCISnapshot":"https://genegraph.clinicalgenome.org/r/10089a58-c9b4-497a-afb0-d249220eb2aa","calculatedEvidenceStrength":"Definitive","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/10089a58-c9b4-497a-afb0-d249220eb2aa_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10027","date":"2023-05-18T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/10089a58-c9b4-497a-afb0-d249220eb2aa_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10027","date":"2023-09-12T20:11:48.680Z","role":"Publisher"}],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/10089a58-c9b4-497a-afb0-d249220eb2aa_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8018bb97-bced-4485-8c63-b2b88b1a6863_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e96d7582-7f4c-4e3c-be7c-f67078f6cc75","type":"EvidenceLine","dc:description":"0.1 (rare and WES + mtDNA done) + 0.4 (reduced MSTO1 by qPCR also 15% on western blot) + 0.4 (fibroblasts show fragmentation of mitochondria network, more abundant altered mitochondria, and fusion events were fewer) + 0.4 (mtDNA depletion in muscle 27% and in fibroblasts 39%)","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/e96d7582-7f4c-4e3c-be7c-f67078f6cc75_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"0.1 (rare and WES + mtDNA done) + 0.4 (reduced MSTO1 by qPCR also 15% on western blot) + 0.4 (fibroblasts show fragmentation of mitochondria network, more abundant altered mitochondria, and fusion events were fewer) + 0.4 (mtDNA depletion in muscle 27% and in fibroblasts 39%)","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/e96d7582-7f4c-4e3c-be7c-f67078f6cc75_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28544275","allele":{"id":"https://genegraph.clinicalgenome.org/r/34548b7f-b319-4904-85ef-488fba707643","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018116.4(MSTO1):c.1128C>A (p.Phe376Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA342759685"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.25},{"id":"https://genegraph.clinicalgenome.org/r/3b484858-335b-4d25-846c-6277bae1f89c","type":"EvidenceLine","dc:description":"0.1 (rare and WES + mtDNA done) + 0.4 (reduced MSTO1 by qPCR also 15% on western blot) + 0.4 (fibroblasts show fragmentation of mitochondria network, more abundant altered mitochondria, and fusion events were fewer) + 0.4 (mtDNA depletion in muscle 27% and in fibroblasts 39%)","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3b484858-335b-4d25-846c-6277bae1f89c_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"0.1 (rare and WES + mtDNA done) + 0.4 (reduced MSTO1 by qPCR also 15% on western blot) + 0.4 (fibroblasts show fragmentation of mitochondria network, more abundant altered mitochondria, and fusion events were fewer) + 0.4 (mtDNA depletion in muscle 27% and in fibroblasts 39%)","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/3b484858-335b-4d25-846c-6277bae1f89c_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28544275","allele":{"id":"https://genegraph.clinicalgenome.org/r/d59e3e6d-af2f-4768-a077-0cdda9fb9f72","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018116.4(MSTO1):c.1033C>T (p.Arg345Cys)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1148106"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.25},{"id":"https://genegraph.clinicalgenome.org/r/8018bb97-bced-4485-8c63-b2b88b1a6863","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28544275","rdfs:label":"Patient A1","ageType":"AgeAtReport","ageUnit":"Months","ageValue":8,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/d59e3e6d-af2f-4768-a077-0cdda9fb9f72"},{"id":"https://genegraph.clinicalgenome.org/r/34548b7f-b319-4904-85ef-488fba707643"}],"detectionMethod":"\"pathogenic mtDNA variants ruled out\", unclear if testing done in blood or muscle\nc.1033C>T; p.R345C (maternally inherited) and c.1128C>A;p.F376L (paternally inherited)\n\np.R345C AF in gnomAD v.3.1.2 0.00004599 (no homozygotes)\np.F376L not reported in gnomAD v.3.1.2\n\nSimilarly affected sister A2 carried both variants as well","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"of cerebellar vermis, with an enlarged cisterna magna, and hyperintense\nsignals in the supratentorial periventricular and posterior white\nmatter.\n","phenotypes":["obo:HP_0000767","obo:HP_0002650","obo:HP_0001270","obo:HP_0001510","obo:HP_0003198","obo:HP_0000580","obo:HP_0001272","obo:HP_0008180"],"previousTesting":true,"previousTestingDescription":"The following genes were previously excluded by Sanger\nsequencing: SPG7, FKTN, POMT1, POMT2, LARGE, POMGNT1, and SIL1.","sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/3b484858-335b-4d25-846c-6277bae1f89c_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/e96d7582-7f4c-4e3c-be7c-f67078f6cc75_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/b56e9de9-bb46-4908-997b-2ab37dc5d3b3_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8cfabc45-4a12-49c3-aaaa-b4cc867c479b","type":"EvidenceLine","dc:description":"0.1 (default) + 0.4 (absent MSTO1 on western blot compared to control) 0.4 (mtDNA depletion) + 0.4 (fewer fused mitochondria and more fragmented mitochondria) ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8cfabc45-4a12-49c3-aaaa-b4cc867c479b_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"fibroblasts show undetectable MSTO1 by WB, mitochondrial fragments without mtDNA genomes, significantly fewer fused mitochondria, reduced mtDNA copy number (50% control), and significantly increased large mtDNA nucleoid","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/8cfabc45-4a12-49c3-aaaa-b4cc867c479b_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31463572","allele":{"id":"https://genegraph.clinicalgenome.org/r/49231ef0-32f5-4a34-abb7-526a5e9c7da2","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018116.4(MSTO1):c.836G>A (p.Arg279His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1148045"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.25},{"id":"https://genegraph.clinicalgenome.org/r/b65e7a50-dea4-4e44-a399-de1fc7ee8ddc","type":"EvidenceLine","dc:description":"0.1 (default) + 0.4 (absent MSTO1 on western blot compared to control) 0.4 (mtDNA depletion) + 0.4 (fewer fused mitochondria and more fragmented mitochondria) ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b65e7a50-dea4-4e44-a399-de1fc7ee8ddc_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":" fibroblasts show undetectable MSTO1 by WB, mitochondrial fragments without mtDNA genomes, significantly fewer fused mitochondria, reduced mtDNA copy number (50% control), and significantly increased large mtDNA nucleoid","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/b65e7a50-dea4-4e44-a399-de1fc7ee8ddc_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31463572","allele":{"id":"https://genegraph.clinicalgenome.org/r/1371bcd1-c2d9-46f9-83e0-7d45c386d381","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018116.4(MSTO1):c.706G>C (p.Asp236His)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1147991"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.25},{"id":"https://genegraph.clinicalgenome.org/r/b56e9de9-bb46-4908-997b-2ab37dc5d3b3","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31463572","rdfs:label":"F1P3","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":6,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/49231ef0-32f5-4a34-abb7-526a5e9c7da2"},{"id":"https://genegraph.clinicalgenome.org/r/1371bcd1-c2d9-46f9-83e0-7d45c386d381"}],"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0004322","obo:HP_0001272","obo:HP_0000750","obo:HP_0002169","obo:HP_0008180","obo:HP_0003198","obo:HP_0001270"],"sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/8cfabc45-4a12-49c3-aaaa-b4cc867c479b_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/b65e7a50-dea4-4e44-a399-de1fc7ee8ddc_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/10089a58-c9b4-497a-afb0-d249220eb2aa_seg_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/0f031154-589f-4177-95d5-e59fd20f7416_proband_segregation","type":"FamilyCosegregation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31463572","rdfs:label":"Donkervoot Family 1","estimatedLodScore":1.33,"family":{"id":"https://genegraph.clinicalgenome.org/r/0f031154-589f-4177-95d5-e59fd20f7416","type":"Family","rdfs:label":"Donkervoot Family 1","member":{"id":"https://genegraph.clinicalgenome.org/r/b56e9de9-bb46-4908-997b-2ab37dc5d3b3"}},"meetsInclusionCriteria":true,"phenotypeNegativeAlleleNegative":1,"phenotypePositiveAllelePositive":3,"phenotypes":["obo:HP_0001272","obo:HP_0003198"],"proband":{"id":"https://genegraph.clinicalgenome.org/r/b56e9de9-bb46-4908-997b-2ab37dc5d3b3"},"sequencingMethod":{"id":"cg:AllGenesSequencing"}}],"specifiedBy":"GeneValiditySegregationEvidenceCriteria","strengthScore":0},{"id":"https://genegraph.clinicalgenome.org/r/4641564e-d56f-4c22-a839-e87e19068a84_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2e7ebe3d-8c8e-4cb0-94aa-44358f3a1a0a","type":"EvidenceLine","dc:description":"0.1 (downgraded splicing variant) + 0.4 (RNA studies show variant results in exon 9 removal only, as opposed to leading to NMD)","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2e7ebe3d-8c8e-4cb0-94aa-44358f3a1a0a_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"0.1 (downgraded splicing variant) + 0.4 (RNA studies show variant results in exon 9 removal)","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/2e7ebe3d-8c8e-4cb0-94aa-44358f3a1a0a_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28544275","allele":{"id":"https://genegraph.clinicalgenome.org/r/ddfc46ac-7a47-4fd3-b302-2154029f322b","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018116.4(MSTO1):c.966+1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1148071"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/56439809-5511-49cd-89af-82ebc49d49a4","type":"EvidenceLine","dc:description":"Score 0.1 for default for rare missense variant with WES ","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/56439809-5511-49cd-89af-82ebc49d49a4_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28544275","allele":{"id":"https://genegraph.clinicalgenome.org/r/099df959-6c6e-4539-a8c1-13882d986d70","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018116.4(MSTO1):c.971C>T (p.Thr324Ile)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1148096"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/4641564e-d56f-4c22-a839-e87e19068a84","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/28544275","rdfs:label":"Patient B","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":1,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/ddfc46ac-7a47-4fd3-b302-2154029f322b"},{"id":"https://genegraph.clinicalgenome.org/r/099df959-6c6e-4539-a8c1-13882d986d70"}],"detectionMethod":"c.971C>T; p.T324I (paternal) and a c.966+1G>A (maternal) affecting the consensus splice site of exon 9 (Fig.1H). Sanger sequencing confirmed the segregation of the mutations\nwith the disease within the family\n\np.T324I AF in gnomAD v3.1.2 0.00003942 (no homozygotes)\nc.966+1G>A AF in gnomAD 0.000006575 (no homozygotes)","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0030234","obo:HP_0001251","obo:HP_0001270","obo:HP_0003198","obo:HP_0001272"],"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/2e7ebe3d-8c8e-4cb0-94aa-44358f3a1a0a_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/56439809-5511-49cd-89af-82ebc49d49a4_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":0.6},{"id":"https://genegraph.clinicalgenome.org/r/f2e997ef-53b4-4738-991f-acc5350380ef_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/12d993f3-d930-4ab0-a394-a756b0252c31","type":"EvidenceLine","dc:description":"Rare missense variant identified in patient via WES default 0.1","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/12d993f3-d930-4ab0-a394-a756b0252c31_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29339779","allele":{"id":"https://genegraph.clinicalgenome.org/r/49231ef0-32f5-4a34-abb7-526a5e9c7da2"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/1e3f50f0-b5da-4cca-992b-afc8e87ae0b1","type":"EvidenceLine","dc:description":"Variant upgraded from default 0.1 to 1.5 based on functional studies showing LOF, no additional functional studies performed. ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/1e3f50f0-b5da-4cca-992b-afc8e87ae0b1_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"RT PCR show variant resulted in exon 11 being 1 bp shorter than that in wild-type cDNA (Fig. 3a), being predicted to cause early truncation of the protein (p.Val367Trpfs*2). Cycloheximide studies suggest mRNA undergoes NMD","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/1e3f50f0-b5da-4cca-992b-afc8e87ae0b1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29339779","allele":{"id":"https://genegraph.clinicalgenome.org/r/47296bae-c7f5-4e68-a566-9519581e65c6","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018116.4(MSTO1):c.1099-1G>A","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1148132"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/f2e997ef-53b4-4738-991f-acc5350380ef","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29339779","rdfs:label":"Iwama et al Patient 1 ","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":5,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/49231ef0-32f5-4a34-abb7-526a5e9c7da2"},{"id":"https://genegraph.clinicalgenome.org/r/47296bae-c7f5-4e68-a566-9519581e65c6"}],"detectionMethod":"mtDNA was not performed \nc.836G>A; p. R279H (pat) gnomAD v.3.1.2 AF 0.00008545 no homoyzgotes \nc.1099-1G>A (mat) not reported in gnomAD v.3.1.2\n--> c.1099-1 G > A resulted in exon 11 being 1 bp shorter than that in wild-type cDNA (Fig. 3a), being predicted to cause early truncation of the protein (p.Val367Trpfs*2)\n\nThe intensity of signal peaks after the splicing mutation increased in the presence of cycloheximide, suggesting that mutant mRNA had been subjected to NMD","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001251","obo:HP_0001272","obo:HP_0001256","obo:HP_0008180","obo:HP_0001510","obo:HP_0002013","obo:HP_0002075","obo:HP_0001270","obo:HP_0002650","obo:HP_0002014","obo:HP_0003198","obo:HP_0000580"],"sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/12d993f3-d930-4ab0-a394-a756b0252c31_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/1e3f50f0-b5da-4cca-992b-afc8e87ae0b1_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/9bc2c455-6ee2-4abf-b984-c2ab79da6035_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5dfb6533-2363-48c0-83c6-6fc110c090e7","type":"EvidenceLine","dc:description":"0.1 + 0.4 (western blot with 50% MSTO1 signal) + 0.4 (reduction in mtDNA content 45% control and increased mitochondrial fragmentation in fibroblasts)","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/5dfb6533-2363-48c0-83c6-6fc110c090e7_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"0.1 + 0.4 (western blot with 50% MSTO1 signal) + 0.4 (reduction in mtDNA content 45% control and increased mitochondrial fragmentation in fibroblasts)","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/5dfb6533-2363-48c0-83c6-6fc110c090e7_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33612823","allele":{"id":"https://genegraph.clinicalgenome.org/r/fcf369a3-b011-4444-9aae-46a7e5f2fbd0","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018116.4(MSTO1):c.1403T>A (p.Leu468Gln)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1148226"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:Homozygous"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/9bc2c455-6ee2-4abf-b984-c2ab79da6035","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33612823","rdfs:label":"Proband Nasca et al 2021","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":2,"allele":{"id":"https://genegraph.clinicalgenome.org/r/fcf369a3-b011-4444-9aae-46a7e5f2fbd0"},"firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001272","obo:HP_0003198","obo:HP_0001251"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/5dfb6533-2363-48c0-83c6-6fc110c090e7_variant_evidence_item"}}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/59dc5701-e93a-47b8-be91-6864b33dae1d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3c9395ac-5dc8-444b-b938-4d48f41996ae","type":"EvidenceLine","dc:description":"0.1 (rare missense variant identified on WES) + 0.4 (WB showing reduced MSTO1) + 0.4 (increased number of partially fragmented mitochondria) ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/3c9395ac-5dc8-444b-b938-4d48f41996ae_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"0.1 (rare missense variant identified on WES) + 0.4 (WB showing reduced MSTO1) + 0.4 (increased number of partially fragmented mitochondria) ","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/3c9395ac-5dc8-444b-b938-4d48f41996ae_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31463572","allele":{"id":"https://genegraph.clinicalgenome.org/r/48cabb22-380a-4ef6-946e-17c941592423","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018116.4(MSTO1):c.651C>G (p.Phe217Leu)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA1147957"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/c324a6a1-9452-4527-babc-68adbd4c43c1","type":"EvidenceLine","dc:description":"0.1 (rare missense variant identified on WES) + 0.4 (WB showing reduced MSTO1) + 0.4 (increased number of partially fragmented mitochondria) ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/c324a6a1-9452-4527-babc-68adbd4c43c1_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Yes (fibroblasts show undetectable MSTO1 by WB + increased number of partially fragmented mitochondria)","functionalDataSupport":"Yes"},{"id":"https://genegraph.clinicalgenome.org/r/c324a6a1-9452-4527-babc-68adbd4c43c1_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31463572","allele":{"id":"https://genegraph.clinicalgenome.org/r/1371bcd1-c2d9-46f9-83e0-7d45c386d381"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/59dc5701-e93a-47b8-be91-6864b33dae1d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31463572","rdfs:label":"Donkervoot P8","ageType":"AgeAtOnset","ageUnit":"Months","ageValue":15,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/1371bcd1-c2d9-46f9-83e0-7d45c386d381"},{"id":"https://genegraph.clinicalgenome.org/r/48cabb22-380a-4ef6-946e-17c941592423"}],"detectionMethod":"Biparentally inherited\n\ngnomAD v.3.1.2\nD236H AF 0.0001248, no homozygotes\nP217L AF 0.0001134, no homozygotes ","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0008180","obo:HP_0001324","obo:HP_0001270","obo:HP_0001251","obo:HP_0003198","obo:HP_0001272","obo:HP_0001310"],"sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/3c9395ac-5dc8-444b-b938-4d48f41996ae_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/c324a6a1-9452-4527-babc-68adbd4c43c1_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/b44cf3a1-dfa0-452f-8faa-459e72db0f78_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/18df019f-53ad-40e3-9552-51d00cb6fdc0","type":"EvidenceLine","dc:description":"Default score for null variant predicted to undergo NMD","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/18df019f-53ad-40e3-9552-51d00cb6fdc0_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30684668","allele":{"id":"https://genegraph.clinicalgenome.org/r/b5d22f44-1d9c-434d-81fa-bacfc40ebfcd","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018116.4(MSTO1):c.1259del (p.Gly420ValfsTer2)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA526669706"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1.5},{"id":"https://genegraph.clinicalgenome.org/r/df52b714-de45-4fd2-b761-61b9cd97a1ec","type":"EvidenceLine","dc:description":"Default Missense variant ","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/df52b714-de45-4fd2-b761-61b9cd97a1ec_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30684668","allele":{"id":"https://genegraph.clinicalgenome.org/r/49231ef0-32f5-4a34-abb7-526a5e9c7da2"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/b44cf3a1-dfa0-452f-8faa-459e72db0f78","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/30684668","rdfs:label":"Li et al 2019 Proband","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":1,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/49231ef0-32f5-4a34-abb7-526a5e9c7da2"},{"id":"https://genegraph.clinicalgenome.org/r/b5d22f44-1d9c-434d-81fa-bacfc40ebfcd"}],"detectionMethod":"p.R279H (0.00008545) in fnomADv3.1.2\np.Gly420ValfsX2 (0.00002632) in gnomAD v3.1.2","firstTestingMethod":"Exome sequencing","phenotypes":["obo:HP_0001270","obo:HP_0003198","obo:HP_0001272","obo:HP_0001249","obo:HP_0004322","obo:HP_0008180"],"secondTestingMethod":"Sanger sequencing","sex":"Male","variant":[{"id":"https://genegraph.clinicalgenome.org/r/18df019f-53ad-40e3-9552-51d00cb6fdc0_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/df52b714-de45-4fd2-b761-61b9cd97a1ec_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.6},{"id":"https://genegraph.clinicalgenome.org/r/61183440-a996-4257-b1b5-4725e1fd1f4f_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d3b83a6c-ed3e-4db4-bb47-5230794d7f12","type":"EvidenceLine","dc:description":"1.5 - 0.5 given occurs in exon 1/14 and could escape NMD","calculatedScore":1.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d3b83a6c-ed3e-4db4-bb47-5230794d7f12_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29339779","allele":{"id":"https://genegraph.clinicalgenome.org/r/b49a1fd7-8277-482d-9993-e4a4cb676530","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_018116.4(MSTO1):c.79C>T (p.Gln27Ter)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA342755801"}},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNullVariantCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/838689b4-83f8-4aa3-b79b-4e2dce6e454e","type":"EvidenceLine","dc:description":"Default missense variant score","calculatedScore":0.1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/838689b4-83f8-4aa3-b79b-4e2dce6e454e_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29339779","allele":{"id":"https://genegraph.clinicalgenome.org/r/49231ef0-32f5-4a34-abb7-526a5e9c7da2"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"paternityMaternityConfirmed":"Yes","zygosity":{"id":"cg:TwoVariantsInTrans"}}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":0.1},{"id":"https://genegraph.clinicalgenome.org/r/61183440-a996-4257-b1b5-4725e1fd1f4f","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29339779","rdfs:label":"Iwama et al Patient 2","ageType":"AgeAtReport","ageUnit":"Years","ageValue":3,"allele":[{"id":"https://genegraph.clinicalgenome.org/r/b49a1fd7-8277-482d-9993-e4a4cb676530"},{"id":"https://genegraph.clinicalgenome.org/r/49231ef0-32f5-4a34-abb7-526a5e9c7da2"}],"detectionMethod":"c.836G>C;p. R279H (pat); AF in gnomAD 0.00008545 no homozygotes\nc.79C>T; p.Gln27X (mat); not reported in gnomAD v.3.1.2","firstTestingMethod":"Exome sequencing","phenotypeFreeText":"multiple arthrogryposis, possible Retinitis pigmentosa","phenotypes":["obo:HP_0001263","obo:HP_0001272","obo:HP_0008180","obo:HP_0001252"],"sex":"Female","variant":[{"id":"https://genegraph.clinicalgenome.org/r/838689b4-83f8-4aa3-b79b-4e2dce6e454e_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/d3b83a6c-ed3e-4db4-bb47-5230794d7f12_variant_evidence_item"}]}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.1}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":12},{"id":"https://genegraph.clinicalgenome.org/r/10089a58-c9b4-497a-afb0-d249220eb2aa_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/10089a58-c9b4-497a-afb0-d249220eb2aa_model_rescue_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/87269889-44c5-4d67-9072-2d1c3a7c1bf6","type":"EvidenceLine","dc:description":"Drosophila study (reduction in brain size corresponds to phenotype and early lethality)\nSince drosophila model only score 0.5\n","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/854ca43f-bf43-41d5-9279-075d802e9579","type":"Finding","dc:description":"Null mutations at the misato locus of Drosophila melanogaster are associated with irregular chromosomal segregation at cell division. The consequences for morphogenesis are that mutant larvae are almost devoid of imaginal disk tissue, have a reduction in brain size, and die before the late third-instar larval stage.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/9144213","rdfs:label":"Null Misato Drosophila","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/5a9b7602-cdb1-4477-85f8-1b6cd46acc4f","type":"EvidenceLine","dc:description":"Scored 0.5 points because of imperfect phenotype overlap - (visceral myopathy v. skeletal myopathy, some evidence for visceral myopathy as well) ","calculatedScore":2,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/03984798-8acf-423b-b629-9a74868e1da0","type":"Finding","dc:description":"In this study, we have shown that depletion of mst in the whole muscle tissues specifically impaired intestinalfunctions while skeletal muscles remained unaffected.\n\nHaving shown that depletion of mst in the Drosophila visceral muscle elicits a series of intestinal phenotypes, we wondered whether genetic restoration of mst expression in mef2 > mst RNAi flies would rescue the phenotypes. By combining UAS-mst transgene with mef2 > mst RNAi flies, we observed that the dilated intestine of mef2 > mst RNAi flies was completely normalized by the restoration of mst expression in the flies","dc:source":"https://pubmed.ncbi.nlm.nih.gov/29255146","rdfs:label":"Misato Drosophila","demonstrates":{"id":"cg:ProteinAlterationDisruptsOrganismFunction"}}],"specifiedBy":"GeneValidityNonHumanModelOrganismCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/bd6e387d-0164-484b-a83b-a64656ab4e14","type":"EvidenceLine","dc:description":"0.5 rescuing mitochondrial fusion, 0.5 for rescuing mitochondrial morphology, 0.5 rescuing mtDNA nucleiod size ","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9d90c1a1-4d0c-440f-8490-75927192bbdd","type":"Finding","dc:description":" The similarity and consistency of the cellular phenotypes described across all seven MSTO1 patient fibroblast lines strongly support the notion that loss of MSTO1 function is the underlying cause responsible for these observations. In order to further confirm that the cellular phenotypes were in fact due to the loss of MSTO1, we transiently expressed wild-type MSTO1 in two of the patient cell lines (P4 and P7) (Fig. 7a, b). Similar to previous reports [16, 35], we found that expression of wild-type MSTO1 restored mitochondrial morphology after 48 h (Fig. 7c). Notably, we also observed more fused mitochondrial networks in control cells overexpressing MSTO1, further validating the role of MSTO1 in promoting fusion. In addition, we also see that lysosome abnormalities are restored (Fig. 7d). While we observed a significant rescue in MSTO1 fibroblasts with regard to mtDNA nucleoid size (Fig. 7e), the number of mtDNA nucleoids did not change in MSTO1 fibroblasts (Fig. 7f). A potential confounding factor is that the transfection protocol itself causes a decrease in mtDNA nucleoid counts, which could be masking a rescue. However, mtDNA copy number was also not rescued after only 48 h (Fig. 7g). This incomplete rescue of mtDNA nucleoid abundance and copy number likely reflects the fact that it may take longer than 48 h for the mtDNA copy number to be re-established.","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31463572","rdfs:label":"Rescue of Mitochondrial Fusion in P4's cells with WTMSTO1","demonstrates":{"id":"cg:PhenotypeRescue"}}],"specifiedBy":"GeneValidityPatientCellRescueCriteria","strengthScore":1.5}],"specifiedBy":"GeneValidityOverallModelAndRescueEvidenceCriteria","strengthScore":2.5},{"id":"https://genegraph.clinicalgenome.org/r/10089a58-c9b4-497a-afb0-d249220eb2aa_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d3ddf6de-daab-4f72-895f-e73439c4f43a","type":"EvidenceLine","dc:description":"Scored 0.5 points for the association with the outer mitochondrial membrane and proposed role in mitochondrial morphology, leading to growth deficiency","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b5da5973-8ca7-4d7b-b104-cbbfb0b057fc","type":"FunctionalAlteration","dc:description":"Mito tracker Orange indicated mitochondrial localization, proteinase K digested Misato indicating its association with the outer mitochondrial membrane\n\nMisato depleted cells had growth deficiencies compared with control siRNA in the transfected cells \nRNAi lead to filamentous appearance of mitochondria network and fragmented mitochondria\n~70% of cells had fragmented mitochondrial with a normal nucleus suggestion Misator plays a role in mitochondrial morphology \n\nNotably, both overexpression and depletion affect cell viability ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/17349998","rdfs:label":"HeLa and COS-7 Cells Studies on Misato"}],"specifiedBy":"GeneValidityNonPatientCellFunctionalAlterationCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/10089a58-c9b4-497a-afb0-d249220eb2aa_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/de83a8b3-2bb6-44ef-8c8e-82fbc2bfc734","type":"EvidenceLine","dc:description":"0.5 per variant for absence MSTO1 on Western Blot","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a78e81b4-b772-406a-a16c-82ddbd4c82ea","type":"Finding","dc:description":"Absence of MSTO1 on Western blot in patients but not control with normal expression of other mitochondrial fusion genes ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31463572","rdfs:label":"Western Blot MSTO1 in P6 FCL","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":1},{"id":"https://genegraph.clinicalgenome.org/r/0a02f594-bf8c-4684-b92f-67d7f7a1f2ea","type":"EvidenceLine","dc:description":"arr[GRCh37] 1q22(155582110_155708204)x1) + p.L450F (in trans)\n0.5 for absence per variant","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b64b0bcf-eef1-4e18-8bdd-21a7b12e8f18","type":"Finding","dc:description":"Absence of MSTO1 on Western blot in patients but not control with normal expression of other mitochondrial fusion genes ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31463572","rdfs:label":"Western Blot MSTO1 in P7 FCL","demonstrates":{"id":"cg:GeneExpressionB"}}],"specifiedBy":"GeneValidityGeneExpressionCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":5}],"evidenceStrength":"Definitive","sequence":6839,"specifiedBy":"GeneValidityCriteria9","strengthScore":17,"subject":{"id":"https://genegraph.clinicalgenome.org/r/xlbTVaJ2v6Y","type":"GeneValidityProposition","disease":"obo:MONDO_0044970","gene":"hgnc:29678","modeOfInheritance":"obo:HP_0000007"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_10089a58-c9b4-497a-afb0-d249220eb2aa-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}